Japan Exports to U.S. Rebound in November as Tariff Impact Eases, Boosting BOJ Rate Hike Expectations 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Asian Stocks Slide as AI Valuation Fears and BOJ Uncertainty Weigh on Markets 
U.S. Dollar Slips Near Two-Month Low as Markets Await Key Jobs Data and Central Bank Decisions 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Asian Stocks Slide as Central Bank Decisions and Key Data Keep Investors Cautious 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Trump Orders Blockade of Sanctioned Oil Tankers, Raising Venezuela Tensions and Oil Prices 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Silver Prices Hit Record High as Safe-Haven Demand Surges Amid U.S. Economic Uncertainty 
Pfizer has acquired a stake in Valneva, a French biotech company, to jointly develop a vaccine for Lyme disease. The former entered into an Equity Subscription Agreement with Valneva and will begin collaboration for the development of a vaccine candidate.
According to Reuters, Pfizer, an American pharmaceutical and biotechnology corporation, will be investing $90.5 million euros or around $95.24 million for the acquisition of an 8.1% stake in Valneva. This is said to represent a price of €9.49 per share, and Pfizer is buying this via a reserved capital increase.
Once it receives the payment from Pfizer, it was reported that the French biotech firm would be using it to support its development contribution to the Lyme disease program, which is already in Phase 3. Pfizer and Valneva also updated the terms of their partnership as well as the license agreement for the VLA15 Lyme disease vaccine candidate. The companies first announced their collaboration in April 2020.
At any rate, Pfizer previously revealed that it is planning to start the Phase 3 study of VLA15 in the Q3 of this year. In the updated deal, Valneva will be funding 40% of the remaining shared costs in the development. Before the revision, the percentage was only 30%.
“Pfizer’s investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva’s vaccine expertise,” Valneva’s chief executive officer, Thomas Lingelbach, said in a press release. “Lyme disease is spreading and impacts the lives of millions of people so we are looking forward to further investigating our VLA15 candidate in Phase 3, which will take us a step closer to potentially help protect both adults and children from this devastating disease.”
Kathrin U. Jansen, Ph.D., Pfizer’s senior vice president and lead of vaccine research & development, further said, “As the geographic footprint of Lyme disease widens, the medical need for vaccination becomes even more imperative and we are excited to continue partnering with Valneva on the development of VLA15.”
Finally, Valneva and Pfizer’s equity investment is set to close on Wednesday, June 22.
